A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

The invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same are also contemplated.

Disclosed herein, are peptides capable of activating proteasome activity, and pharmaceutical compositions containing the peptides and methods treating Alzheimer's disease. Disclosed herein are compositions comprising: A) a peptide, wherein the peptide comprises the amino acid sequence GRKKR-RQ-AibG-RPS (SEQ ID NO: 4), or a fragment or variant thereof, B) a peptide, wherein the peptide comprises the amino acid sequence GRKKRRQ-AibG-QR-RKKRG (SEQ ID NO: 5), or a fragment or variant thereof, or C) a peptide, wherein the peptide comprises the amino acid sequence KKK/KKK-DABA-K KK (SEQ ID NO: 6) or a fragment or variant thereof.

Disclosed herein, are peptides capable of activating proteasome activity, and pharmaceutical compositions containing the peptides and methods treating Alzheimer's disease. Disclosed herein are compositions comprising: A) a peptide, wherein the peptide comprises the amino acid sequence GRKKR-RQ-AibG-RPS (SEQ ID NO: 4), or a fragment or variant thereof, B) a peptide, wherein the peptide comprises the amino acid sequence GRKKRRQ-AibG-QR-RKKRG (SEQ ID NO: 5), or a fragment or variant thereof, or C) a peptide, wherein the peptide comprises the amino acid sequence KKK/KKK-DABA-K KK (SEQ ID NO: 6) or a fragment or variant thereof.

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary/breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and/or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary/breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and/or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.

The present application is directed to cargo delivery complexes for intracellular delivery of a cargo molecule comprising: a first peptide comprising a cell-penetrating peptide (CPP), a second peptide comprising a cell-penetrating peptide, and a cargo molecule. The second peptide comprises a polyethylene glycol (PEG) moiety linked to the second CPP, and the first peptide does not have a PEG moiety. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the CPP is a retro-inverso peptide. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the peptide further comprises a targeting sequence selected from the group consisting of GYVSK, GYVS, YIGS and YIGSR. Methods of making and using the cargo delivery complexes are also disclosed.